


RAW SEQUENCE LISTING ERROR REPORT

BIOTECHNOLOGY
SYSTEMS
BRANCH



2590
1108

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 4/06/01 07/977,283
Source: OIRE
Date Processed by STIC: 11/06/01

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:

Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 - 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO). Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:

<http://www.uspto.gov/web/offices/pac/checker>

BEST AVAILABLE COPY

Raw Sequence Listing Error Summary

ERROR DETECTED

SUGGESTED CORRECTION

SERIAL NUMBER: 11/06/01

ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY P

- 1 Wrapped Nucleics
 Wrapped Amino
The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to 3; this will prevent "wrapping."
- 2 Invalid Line Length
The rules require that a line not exceed 72 characters in length. This includes white spaces.
- 3 Misaligned Amino
 Numbering
The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
- 4 Non-ASCII
The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
- 5 Variable Length
Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
- 6 PatentIn 2.0
 "bug"
A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
- 7 Skipped Sequences
 (OLD RULES)
Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence
(2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
(i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading)
(xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown)
This sequence is intentionally skipped

Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
- 8 Skipped Sequences
 (NEW RULES)
Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence:
<210> sequence id number
<400> sequence id number
000
- 9 ✓ Use of n's or Xaa's
 (NEW RULES)
Use of n's and/or Xaa's have been detected in the Sequence Listing.
Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present.
In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents
- 10 Invalid <213>
 Response
Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or Artificial Sequence
- 11 Use of <220>
Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses.
Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section.
(See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
- 12 PatentIn 2.0
 "bug"
Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
- 13 Misuse of n
n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

OIPE

RAW SEQUENCE LISTING

DATE: 11/06/2001

PATENT APPLICATION: US/09/977,283

TIME: 12:08:08

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

5 <110> APPLICANT: Reed, Guy L.
 9 <120> TITLE OF INVENTION: Composition and Method for Enhancing Fibrinolysis
 13 <130> FILE REFERENCE: 0609.4320003
 C--> 17 <140> CURRENT APPLICATION NUMBER: US/09/977,283 *ok*
 C--> 19 <141> CURRENT FILING DATE: 2001-10-16
 23 <150> PRIOR APPLICATION NUMBER: 08/934,000
 25 <151> PRIOR FILING DATE: 1997-09-19
 29 <150> PRIOR APPLICATION NUMBER: 60/026,356
 31 <151> PRIOR FILING DATE: 1996-09-20
 35 <160> NUMBER OF SEQ ID NOS: 81
 39 <170> SOFTWARE: PatentIn version 3.1
 43 <210> SEQ ID NO: 1
 45 <211> LENGTH: 15
 47 <212> TYPE: PRT
 49 <213> ORGANISM: Artificial Sequence
 53 <220> FEATURE:
 55 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 58 <220> FEATURE:
 60 <221> NAME/KEY: MISC_FEATURE
 62 <222> LOCATION: (1)..(1)
 64 <223> OTHER INFORMATION: May be any Amino Acid
 68 <400> SEQUENCE: 1
 W--> 70 *Xaa* Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val
 1 5 10 15
 74 <210> SEQ ID NO: 2
 76 <211> LENGTH: 5
 78 <212> TYPE: PRT
 80 <213> ORGANISM: Artificial Sequence
 84 <220> FEATURE:
 86 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 88 <400> SEQUENCE: 2
 90 Asp Ile Gln Met Thr
 91 1 5
 94 <210> SEQ ID NO: 3
 96 <211> LENGTH: 15
 98 <212> TYPE: PRT
 100 <213> ORGANISM: Artificial Sequence
 104 <220> FEATURE:
 106 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
 108 <220> FEATURE:
 110 <221> NAME/KEY: MISC_FEATURE
 112 <222> LOCATION: (1)..(1)
 114 <223> OTHER INFORMATION: May be any Amino Acid
 118 <400> SEQUENCE: 3
 W--> 120 *Xaa* Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val
 1 5 10 15
 124 <210> SEQ ID NO: 4

Does Not Comply
 Corrected Diskette Needed

See page 2 of 7

RAW SEQUENCE LISTING

DATE: 11/06/2001

PATENT APPLICATION: US/09/977,283

TIME: 12:08:08

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

126 <211> LENGTH: 381

128 <212> TYPE: DNA

130 <213> ORGANISM: Artificial Sequence

134 <220> FEATURE:

136 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody

138 <220> FEATURE:

140 <221> NAME/KEY: CDS

142 <222> LOCATION: (1)..(381)

144 <223> OTHER INFORMATION:

148 <220> FEATURE:

150 <221> NAME/KEY: sig_peptide

152 <222> LOCATION: (1)..(60)

154 <223> OTHER INFORMATION:

158 <400> SEQUENCE: 4

W--> 159 atg agt gtg ctc act cag gtc ctg ggg ttg ctg ctg ctg tgg ctt aca 48

160 Met Ser Val Leu Thr Gln Val Leu Xaa Leu Leu Leu Leu Trp Leu Thr

161 -20 -15 -10 -5

163 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct 96

164 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser

165 1 5 10

167 gca tct gtg gga gaa act gtc acc atc aca tgt cga gca agt ggg aat 144

168 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn

169 15 20 25

171 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tct cct 192

172 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro

173 30 35 40

175 cag ctc ctg gtc tat aat gca aaa acc tta gca gat ggt gtg cca tca 240

176 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser

177 45 50 55 60

179 agg ttc agt ggc agt gga tca gga aca caa ttt tct ctc agg atc aac 288

180 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn

181 65 70 75

183 agc ctg cag cct gaa gat ttt ggg agt cat tac tgt caa cat ttt tgg 336

184 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp

185 80 85 90

187 acc act ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa 381

188 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys

189 95 100 105

192 <210> SEQ ID NO: 5

194 <211> LENGTH: 127

196 <212> TYPE: PRT

198 <213> ORGANISM: Artificial Sequence

202 <220> FEATURE:

204 <221> NAME/KEY: MISC_FEATURE

206 <222> LOCATION: (9)..(9)

208 <223> OTHER INFORMATION: May be either Gly or Ala

210 <220> FEATURE:

212 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody

214 <400> SEQUENCE: 5

Does Not Comply
Corrected Diskette Needed

Does Not Comply
Corrected Diskette Needed

Emmed: Xaa should be explained in

good

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/977,283

DATE: 11/06/2001

TIME: 12:08:08

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

```

W--> 216 Met Ser Val Leu Thr Gln Val Leu Xaa Leu Leu Leu Leu Trp Leu Thr
217 -20 -15 -10 -5
220 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
221 1 5 10
224 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
225 15 20 25
228 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
229 30 35 40
232 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
233 45 50 55 60
236 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Arg Ile Asn
237 65 70 75
240 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
241 80 85 90
244 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
245 95 100 105
248 <210> SEQ ID NO: 6
250 <211> LENGTH: 381
252 <212> TYPE: DNA
254 <213> ORGANISM: Artificial Sequence
258 <220> FEATURE:
260 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
262 <220> FEATURE:
264 <221> NAME/KEY: CDS
266 <222> LOCATION: (1)..(381)
268 <223> OTHER INFORMATION:
272 <220> FEATURE:
274 <221> NAME/KEY: sig_peptide
276 <222> LOCATION: (1)..(60)
278 <223> OTHER INFORMATION:
282 <400> SEQUENCE: 6
283 atg agt gtg ctc act cag gtc ctg ggg ttg ctg ctg ctg tgg ctt aca 48
284 Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Trp Leu Thr
285 -20 -15 -10 -5
287 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct 96
288 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
289 1 5 10
291 gca tct gtg gga gaa act gtc acc gtc aca tgt cga gca agt ggg aat 144
292 Ala Ser Val Gly Glu Thr Val Thr Val Thr Cys Arg Ala Ser Gly Asn
293 15 20 25
295 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tct cct 192
296 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
297 30 35 40
299 cag ctc ctg gtc tat aat gca aga acc tta gca gat ggt gtg cca tca 240
300 Gln Leu Leu Val Tyr Asn Ala Arg Thr Leu Ala Asp Gly Val Pro Ser
301 45 50 55 60
303 agg ttc agt ggc agt gga tca gga aca caa tat tct ctc aag atc aac 288
304 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn
305 65 70 75

```

RAW SEQUENCE LISTING

DATE: 11/06/2001

PATENT APPLICATION: US/09/977,283

TIME: 12:08:08

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

```

307 agc ctg cag cct gaa gat ttt ggg agt tat tac tgt caa cat ttt tgg      336
308 Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp
309          80          85          90
311 agt aat ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa      381
312 Ser Asn Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
313          95          100          105
316 <210> SEQ ID NO: 7
318 <211> LENGTH: 127
320 <212> TYPE: PRT
322 <213> ORGANISM: Artificial Sequence
326 <220> FEATURE:
328 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
330 <400> SEQUENCE: 7
332 Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
333 -20          -15          -10          -5
336 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
337          1          5          10
340 Ala Ser Val Gly Glu Thr Val Thr Val Thr Cys Arg Ala Ser Gly Asn
341          15          20          25
344 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
345          30          35          40
348 Gln Leu Leu Val Tyr Asn Ala Arg Thr Leu Ala Asp Gly Val Pro Ser
349 45          50          55          60
352 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn
353          65          70          75
356 Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp
357          80          85          90
360 Ser Asn Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
361          95          100          105
364 <210> SEQ ID NO: 8
366 <211> LENGTH: 381
368 <212> TYPE: DNA
370 <213> ORGANISM: Artificial Sequence
374 <220> FEATURE:
376 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
378 <220> FEATURE:
380 <221> NAME/KEY: CDS
382 <222> LOCATION: (1)..(381)
384 <223> OTHER INFORMATION:
388 <220> FEATURE:
390 <221> NAME/KEY: sig_peptide
392 <222> LOCATION: (1)..(60)
394 <223> OTHER INFORMATION:
398 <400> SEQUENCE: 8
399 atg agt gtg ctc act cag gtc ctg gcg ttg ctg ctg ctg tgg ctt aca      48
400 Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr
401 -20          -15          -10          -5
403 ggt gcc aga tgt gac atc cag atg act cag tct cca gcc tcc cta tct      96
404 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser

```

RAW SEQUENCE LISTING

DATE: 11/06/2001

PATENT APPLICATION: US/09/977,283

TIME: 12:08:08

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

```

405              1              5              10
407 gca tct gtg gga gaa act gtc acc atc aca tgt cga gca agt ggg aat      144
408 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
409              15              20              25
411 att cac aat tat tta gca tgg tat cag cag aaa cag gga aaa tct cct      192
412 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
413              30              35              40
415 caa ctc ctg gtc tat aat gca aaa acc tta gca gat ggt gtg cca tca      240
416 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
417 45              50              55              60
419 agg ttc agt ggc agt gga tca gga aca caa ttt tct ctc aag atc aac      288
420 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
421              65              70              75
423 agc ctg cag cct gaa gat ttt ggg agt cat tac tgt caa cat ttt tgg      336
424 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
425              80              85              90
427 acc act ccg tgg acg ttc ggt gga ggc acc aag ctg gaa atc aaa      381
428 Thr Thr Pro Trp Thr Phe Gly Gly Thr Lys Leu Glu Ile Lys
429              95              100              105
432 <210> SEQ ID NO: 9
434 <211> LENGTH: 127
436 <212> TYPE: PRT
438 <213> ORGANISM: Artificial Sequence
442 <220> FEATURE:
444 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
446 <400> SEQUENCE: 9
448 Met Ser Val Leu Thr Gln Val Leu Ala Leu Leu Leu Leu Trp Leu Thr
449 -20              -15              -10              -5
452 Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
453              1              5              10
456 Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
457              15              20              25
460 Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
461              30              35              40
464 Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
465 45              50              55              60
468 Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Phe Ser Leu Lys Ile Asn
469              65              70              75
472 Ser Leu Gln Pro Glu Asp Phe Gly Ser His Tyr Cys Gln His Phe Trp
473              80              85              90
476 Thr Thr Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
477              95              100              105
480 <210> SEQ ID NO: 10
482 <211> LENGTH: 414
484 <212> TYPE: DNA
486 <213> ORGANISM: Artificial Sequence
490 <220> FEATURE:
492 <223> OTHER INFORMATION: Alpha-2 Antiplasmin Antibody
494 <220> FEATURE:

```

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/977,283

DATE: 11/06/2001

TIME: 12:08:09

Input Set : A:\Sequence listing ascii

Output Set: N:\CRF3\11062001\I977283.raw

L:17 M:270 C: Current Application Number differs, Replaced Application Number
L:19 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:70 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1
L:120 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:3
L:160 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4
L:216 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5
L:516 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:10
L:584 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:11
L:656 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:12
L:723 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:13
L:795 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:14
L:863 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:15
L:1296 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22
L:1324 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23
L:2415 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2423 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2427 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2431 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:75
L:2481 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:76
L:2649 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2653 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2661 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2665 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2669 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:77
L:2793 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:2809 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:2813 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:78
L:2935 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:2943 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:2947 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:2951 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:79
L:3033 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3045 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3049 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:80
L:3287 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3291 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3295 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3299 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3303 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3307 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81
L:3315 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:81